Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Ebit" stands at 32.17 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Johnson & Johnson's third quarter result of 7.51 Billion USD for the item "Ebit" represents an increase of 10.47 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 7.51 Billion USD for the item "Ebit" represents an increase of 112.72 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 32.17 Billion USD for the item "Ebit" represents an increase of 14.12 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 74.88 percent compared to the value the year prior.
The 1 year change in percent is 74.88.
The 3 year change in percent is 40.21.
The 5 year change in percent is 66.96.
The 10 year change in percent is 72.28.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Ebit | 905,699,262,464.00 |
![]() | AbbVie Inc - Ebit | 399,570,305,024.00 |
![]() | Roche Holding AG - Ebit | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Ebit | 280,205,508,085.11 |
![]() | Novartis AG - Ebit | 255,096,620,580.91 |